Summary:
- The article discusses an update on the FDA's review of Ruxolitinib cream, also known as Opzelura, for the treatment of children aged 8 and older with atopic dermatitis.
- Atopic dermatitis is a chronic skin condition that causes red, itchy, and inflamed skin. Ruxolitinib cream is a potential new treatment option for children with this condition.
- The FDA is currently reviewing the data and information submitted by the pharmaceutical company Incyte, which developed Ruxolitinib cream. The review is ongoing, and the FDA will make a decision on whether to approve the treatment for use in children in the future.